Publications Fredrik Swartling

Publications in DiVA

Publications in PubMed

Selected publications

  1. Mainwaring O*, Weishaupt H*, Zhao M, Rosén G, Borgenvik A, Breinschmid L, Veerbaan AD, Richardson S, Thompson D, Clifford SC, Hill RH, Annusver K, Sundström A, Holmberg KO, Kasper M, Hutter S and Swartling FJ. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors. Nature Comms. Accepted. (2023).
  2. Weishaupt H*, Čančer M*, Rosén G, Holmberg KO, Häggqvist S, Ignas Bunikis, Jiang Y, Sreedharan SS, Gyllensten U, Becher OJ, Uhrbom L, Ameur A, Swartling FJ. Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas. Neuro-Oncology. 2023, 25(1):97-107.
  3. Borgenvik A*, Holmberg KO*, Bolin S*, Zhao M, Savov V, Rosén G, Hutter S, Garancher A, Rahmanto AS, Bergström T, Mainwaring O, Rusert J, Sundström A, Ballester Bravo M, Richardson S, Fotaki G, Hill RM, Dubuc A, Kalushkova A, Remke M, Čančer M, Jernberg-Wiklund H, Giraud G, Sangfelt O, Taylor MD, Clifford SC, Schüller U, Wechsler-Reya RJ, Weishaupt H and Swartling, FJ. Dormant SOX9-positive cells facilitate MYC-driven medulloblastoma recurrence. Cancer Res. 2022, 82(24):4586-4603.
  4. Hovestadt V, Ayrault O, Swartling FJ, Robinson GW, Pfister SM, Northcott PA. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat Rev Cancer. 2020, 20(1):42-56.
  5. Čančer M, Hutter S, Holmberg KO, Rosén G, Sundström A, Tailor J, Bergström T, Garancher A, Essand M, Wechsler-Reya RJ, Falk A, Weishaupt H, Swartling FJ. Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. 2019, Cell Stem Cell. 25(6):855-870.e11.
  6. Weishaupt H, Johansson P, Sundström A, Lubovac-Pilav Z, Olsson B, Nelander S and Swartling FJ. Batch-normalization of cerebellar and medulloblastoma gene expression datasets utilizing empirically defined negative control genes. Bioinformatics. 2019, 35(18):3357-3364.
  7. Bolin S, Borgenvik A, Persson CU, Sundström A, Qi, J, Weiss WA, Cho J-Y, Bradner, JE, Weishaupt H, Swartling FJ. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. Oncogene 2018, 37:2850-2862.
  8. Suryo Rahmanto A*,1, Savov V*, Brunner AW, Bolin S, Weishaupt H, Čančer M, Rosén G, Hutter S, Sundström A, Kawauchi D, Jones DT, Spruck C, Taylor MD, Maljukova A, Cho YJ, Pfister SM, Kool M, Korshunov A, Swartling FJ*# and Sangfelt O*#. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J. 2016, 35:2192-2212. 
  9. Swartling FJ#, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, Grimmer MR, Lau J, Chesler L, Perry A, Phillips JJ, Taylor MD, Weiss WA#. Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. Cancer Cell. 2012, 21(5):601-13.
  10. Swartling FJ*, Grimmer MR*, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Collins R, Nguyen K, Yakovenko S, Zhe XN, Flynn Gilmer HC, Nagaoka M, Phillips JJ, Jenkins RB, Tihan T, Vandenberg SR, James CD, Tanaka K, Taylor MD, Weiss WA# and Chesler L#. Pleiotropic role for MYCN in medulloblastoma. Genes & Dev. 2010, 24:1059-72.

*, #: shared authors/equal contribution

Last modified: 2023-02-20
Print